Jeffrey Cohen, MD
Pulmonary Disease · Jonesboro, ARNPI 1710973979
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,151 of the $7,949 with a category attached, or 90.0%. It is spread thinly across 40 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations.
Across 439 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$1K
- Intuitive Surgical$652
- Boehringer Ingelheim$578
- Jazz Pharmaceuticals Inc.$442
- Regeneron Healthcare Solutions, Inc.$409
- plus $3K from 34 others
What the payments were for
- Consulting fees$2003%
- Travel & lodging$2974%
- Food & beverage$7,15190%
- Education$1302%
- Gifts$1712%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 107 | $1,343 |
| AstraZeneca | 75 | $1,214 |
| Intuitive Surgical | 5 | $652 |
| Boehringer Ingelheim | 43 | $578 |
| Jazz Pharmaceuticals Inc. | 23 | $442 |
| Regeneron Healthcare Solutions, Inc. | 17 | $409 |
| Mylan Specialty L.p. | 20 | $337 |
| Insmed, Inc. | 14 | $284 |
| Genentech USA, Inc. | 20 | $269 |
| Sanofi | 13 | $258 |
| Inspire Medical Systems, Inc. | 4 | $250 |
| Bayer | 2 | $215 |
| Actelion Pharmaceuticals US, Inc. | 12 | $182 |
| Pulmonx Corporation | 6 | $181 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $157 |
| Novartis | 7 | $121 |
| Amgen | 6 | $117 |
| Pfizer | 7 | $111 |
| Teva Pharmaceuticals USA, Inc. | 7 | $102 |
| AbbVie(2 entities) | 5 | $77 |
| Philips North America LLC | 4 | $73 |
| Grifols USA, LLC | 4 | $65 |
| Medtronic | 1 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| Boston Scientific | 3 | $41 |
| Baxter Healthcare | 2 | $40 |
| Merck | 3 | $37 |
| United Therapeutics Corporation | 2 | $37 |
| Mallinckrodt Hospital Products Inc. | 2 | $35 |
| Mallinckrodt Enterprises LLC | 2 | $32 |
| Vifor Pharma, Inc. | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $30 |
| Averitas Pharma Inc. | 1 | $23 |
| Inogen, Inc. | 1 | $20 |
| Veran Medical Technologies, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Fisher & Paykel Healthcare Inc | 1 | $14 |
| Abbott | 1 | $13 |
| Advanced Respiratory, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,949 in reported general payments places this provider in the 70th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KalydecoIvacaftor | 15 | $369,947 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 294 | $207,783 |
| OpsumitMacitentan | 15 | $188,810 |
| GlassiaAlpha-1-Proteinase Inhibitor | 17 | $159,033 |
| Dupixent PenDupilumab | 29 | $109,383 |
| NucalaMepolizumab | 17 | $61,502 |
| Breo ElliptaFluticasone/Vilanterol | 91 | $40,055 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $24,683 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $16,931 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 35 | $16,291 |
| Spiriva HandihalerTiotropium Bromide | 22 | $15,154 |
| Arnuity ElliptaFluticasone Furoate | 36 | $11,718 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $9,248 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 67 | $8,976 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $7,887 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,343 | $345,875501 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $182 | $188,81015 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $157 | $159,03317 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,214 | $33,93175 claims |
| Boehringer IngelheimStiolto Respimat | $578 | $16,29135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Jonesboro
- Mark SiffordJonesboro$20K
- George Williams IiJonesboro$10K
- Grant CagleJonesboro$6K
- Mohammad AlnabulsiJonesboro$5K
- Joshua MorrisonJonesboro$3K
- Ladly AbrahamConway$371K
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Arturo MeadeFort Smith$67K
- Nikhil MeenaLittle Rock$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.